Moderna's stock plunged on Thursday, startling investors. But the company remains one of this year’s hottest biotech ...

Moderna gave investors a scare as its stock plunged on Thursday. But it's still one of the hottest biotechs this year. And it's hardly alone – the sector is on a roll and looks poised for more gains.

A study of a personalized vaccine combined with an existing immunotherapy found the treatment helped patients with melanoma avoid cancer recurrence. The combination trains the patient's immune system ...

When a drugmaker's top product loses patent protection, the dividend usually takes the hit. Four pharma giants are each ...

Moderna is rated a Hold, citing valuation concerns, lack of definitive long-term efficacy data, and significant execution and ...

Moderna and Merck are preparing to seek regulatory approval after their experimental melanoma vaccine delivered promising ...

A new personalized mRNA vaccine for melanoma is being hailed by some oncologists as a major breakthrough after it reduced the risk of cancer recurrence and death by 42% compared with standard ...

When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage clinical trial in melanoma, oncologists and the public alike were ...

Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful advance in melanoma ...

Moderna launched its coronavirus vaccine in early pandemic days and saw revenue and stock performance skyrocket. As demand ...

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top ...

The vaccine, called intismeran, is tailored to each patient’s tumour. The findings, which measured recurrence risk over two ...